Past

We were thrilled to hold the Software Crafters Leeds event in October, co-hosted by Codurance. This event was for those who have ever been curious about the world of scientific software development – specifically how software can be built to predict complex scientific outcomes, without specialised scientific knowledge. The event kicked off with a brief

The 50th OPRD Conference was held in October in Barcelona! The event provided scientific content alongside the renowned networking receptions. The conference provided scientists the opportunity to improve efficiency and learn how to be more innovative in synthetic route design, development, and optimisation. The chemical and pharma industries are fast moving and ever changing and

In a world where the desire to create a positive impact on society and the environment is growing, the significance of purpose-driven work is becoming increasingly evident. Recent research by McKinsey & Co revealed that 70 percent of employees now derive their sense of purpose from work, presenting a promising opportunity for Tech4Good organisations. At

We were delighted announce that Lhasa Principal Scientist, Alun Myden presented our award winning paper ‘Using adverse outcome pathways to contextualise (Q)SAR predictions for reproductive toxicity – A case study with aromatase inhibition’, at the 51st Annual meeting of the ETS conference. The award winning-paper, co-authored by Senior Scientist, Emma White and Head of Toxicology,

We were excited to attend the International Society for the Study of Xenobiotics meeting, in Boston, Massachusetts! The meeting, one of the world’s largest gatherings of researchers in xenobiotics, offered innovative short courses, symposia, lectures and other events. It provided an exceptional opportunity for researchers, from academia and industry alike, to gather, network, and exchange

We were excited to attend EUROTOX 2023, which took place from 10 to 13 September in Slovenia! Monday 11th September, 09:30 AM. Scientist, Tasha Jones presented “Development of a network of adverse outcome pathways (AOPs) associating immunosuppression with cancer”. The poster itself outlines a preliminary network of AOPs linking MIEs leading to immunosuppression and resulting